|Bid||11.90 x 500|
|Ask||18.00 x 1000|
|Day's Range||13.55 - 13.90|
|52 Week Range||4.40 - 14.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MediciNova Inc (NASDAQ:MNOV), a US$450.62M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impactingRead More...
On February 12, 2018, MediciNova (MNOV) announced the closing of an underwritten public offering of approximately 4.4 million shares of its common stock at a price of $9.05 per share, which resulted in gross proceeds to the company of approximately $40 million. The company also granted the underwriters a 30-day option to purchase up to an additional 662,983 shares at the public offering price less underwriting discounts. On February 13, 2018, MediciNova filed form 10-K with financial results for the fourth quarter and full year 2017.
The data showed that treatment with MN-166 resulted in a 26% reduction in confirmed disability progression, which was a secondary endpoint in the Phase 2 trial but which would be a primary endpoint in a Phase 3 trial. The company had previously announced positive topline data showing a statistically significant 48% reduction in the rate of progression of whole brain atrophy compared to placebo (P=0.04). The following graph shows a Kaplan-Meier plot of confirmed EDSS progression along with the absolute numbers of patients with confirmed EDSS progression.
In this analysis, my focus will be on developing a perspective on MediciNova Inc’s (NASDAQ:MNOV) latest ownership structure, a less discussed, but important factor. Ownership structure has been found toRead More...
Yuichi Iwaki took the reins as CEO of MediciNova Inc’s (NASDAQ:MNOV) and grew market cap to $252.71M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...
The latest earnings update MediciNova Inc’s (NASDAQ:MNOV) released in September 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below isRead More...
After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compareRead More...
The primary endpoint of the study (safety and tolerability) was achieved and there were efficacy trends in key functional secondary endpoints that favored MN-166. This was a single center, double blind, placebo controlled six-month study with patients randomized 2:1 to receive riluzole (100 mg/day) plus either MN-166 (60 mg/day) or placebo. The six-month double blind portion was followed by a six-month open label extension phase during which all patients received MN-166.
MediciNova Inc (NASDAQ:MNOV), a USD$251.26M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoingRead More...
MediciNova Inc (NASDAQ:MNOV), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. As aRead More...
On June 5, 2017, MediciNova (MNOV) announced that Professor Kerrie McDonald presented results from a preclinical study of MN-166 (ibudilast) in the treatment of glioblastoma (GBM) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Proteomic profiling of samples from 30 GBM patients revealed macrophage inhibitory factor (MIF) as a protein that was expressed in “poor responders” (e.g., those that lived